首页> 美国卫生研究院文献>The Canadian Journal of Cardiology >Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

【2h】

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

机译：在加拿大大剂量（80 mg /天）阿托伐他汀治疗与标准剂量（20 mg /天至40 mg /天）辛伐他汀治疗相比经济价值的评估是基于降低的激进性降脂终点（IDEAL））试用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND:The Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial demonstrated incremental cardiovascular benefit of treatment with high-dose atorvastatin (80 mg/day) versus standard-dose simvastatin (20 mg/day to 40 mg/day) in 8888 patients with a previous myocardial infarction (MI) over a median follow-up period of 4.8 years.

机译：背景：通过降低激进的降脂（IDEAL）试验使终点值逐渐降低表明，与标准剂量辛伐他汀（20 mg /天至40 mg /天）相比，大剂量阿托伐他汀（80 mg /天）治疗对心血管的益处增加在中位随访时间为4.8年的8888名先前有心肌梗死（MI）的患者中。

著录项

期刊名称 The Canadian Journal of Cardiology
作者
Monika Wagner; Peter Lindgren; Elizabeth Merikle; Mireille Goetghebeur; Bengt Jönsson;
展开▼
作者单位

展开▼
年(卷),期 2009(25),11
年度 2009
页码 e362–e369
总页数 8
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
Atorvastatin Clinical outcomes Cost-effectiveness Cost utility Markov model Simvastatin;

机译：阿托伐他汀;临床结果;成本效益;成本效用;马尔可夫模型;辛伐他汀;

相似文献

外文文献
中文文献

1. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) trial). [J] . Pedersen TR, Cater NB, Faergeman O, The American Journal of Cardiology . 2010,第3期

机译：阿托伐他汀80毫克/天与辛伐他汀20至40毫克/天在急性心肌梗死后晚期（五年）心血管事件发生频率的比较（通过积极的降脂试验（IDEAL）使终点增加）。
2. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering (IDEAL) study). [J] . Tikkanen MJ, Holme I, Cater NB, The American Journal of Cardiology . 2009,第5期

机译：在65岁以下或≥65岁的冠心病患者中，阿托伐他汀（80毫克）与辛伐他汀（20至40毫克）的疗效和安全性比较（来自通过积极降脂（IDEAL）进行的增量减少）。
3. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. [J] . Barrios V, Amabile N, Paganelli F, International journal of clinical practice . 2005,第12期

机译：在动脉粥样硬化或冠心病的高胆固醇血症患者中，将阿托伐他汀10 mg /天转换为依泽替米贝/辛伐他汀10/20 mg /天的脂质改变功效。
4. A Computer Based Blastomere Identification and Evaluation Method for Day 2 Embryos During IVF/ICSI Treatments [C] . Charalambos Strouthopoulos, Athanasios Nikolaidis International work-conference on bioinformatics and biomedical engineering . 2019

机译：IVF / ICSI处理过程中第2天胚胎的基于计算机的卵裂球鉴定和评估方法
5. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial [O] . Stephen B Hanauer, William J Sandborn, Christian Dallaire, 2007

机译：口服缓释美沙明胺4.8 g /天（800 mg片）与2.4 g /天（400 mg片）相比用于治疗轻度至中度活动性溃疡性结肠炎：ASCEND I试验
6. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial [O] . Wagner, Monika, Lindgren, Peter, Merikle, Elizabeth, 2009

机译：在加拿大，大剂量（80 mg /天）阿托伐他汀治疗与标准剂量（20 mg /天至40 mg /天）辛伐他汀治疗相比，经济价值的评估是基于降低的激进性降脂终点（IDEAL））试用

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

摘要

著录项

相似文献

相关主题

期刊订阅